Do you have dry Macular Degeneration ?


16586

A Randomized, Double Masked, Placebo Controlled Study Evaluating ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration

Ophthalmology

Yates Paul, A

The purpose of this 31 month study is to test the safety and effectiveness of an investigational drug called ORACEA® (40mg doxycycline), to determine if it can slow the progression of geographic atrophy secondary to non-exudative (“dry”) age-related macular degeneration. You may qualify for this study if you: 1. Are between 55 – 85 years of age. 2. Have geographic atrophy secondary to dry AMD in at least one eye 3. Your visual acuity is between 20/20 – 20/400 in the study eye 4. Do NOT have a history of or active wet AMD in the study eye 5. Do NOT have a history of or active wet AMD in the non-study eye that has needed treatment within 12 months of starting the study What is involved? After completing a screening and 6-month observation period, eligible participants will be randomized (like the flip of a coin) to one of two study drug groups (1 group receives the study drug and 1 group receives a placebo). No matter what group you are assigned, you will take one capsule of the study drug every morning. You will do this every day for 24 months. For more information about this study please contact the Study Coordinator, Kristina Holbrook, at (434) 243-2852 or klh7v@virginia.edu or visit: http://www.clinicaltrials.gov/ct2/show/NCT1342926?term=gsk+geographic+atrophy&rank=1 The principal investigator is Paul Yates, MD, PhD.


Adult

Macular Degeneration

Ophthalmology

Ill

No Compensation

Kristina Holbrook

klh7v@virginia.edu

4342432852